Discover how metformin, the inexpensive generic diabetes medication, helped one patient halt severe lupus progression — and what the latest science says about its potential.
The promise of metformin for treating lupus
Metformin is widely recognized as the first-line defense against type 2 diabetes. Like many medications, it also has broader effects. The Parsemus Foundation has advocated investigating metformin’s capacity to influence multiple physiological systems beyond blood sugar control.
Emerging research suggests that metformin may hold significant promise for autoimmune conditions such as lupus (Systemic Lupus Erythematosus or SLE). People with lupus experience a wide range of symptoms because their immune system attacks their tissues and organs, causing inflammation. This autoimmune disease can affect most body systems, including:
- cardiovascular
- gastrointestinal
- hematologic (blood)
- integumentary (blood/skin/nails)
- musculoskeletal
- neuropsychiatric
- pulmonary
- renal
- reproductive
Metformin users have lower lupus health impacts
Of particular significance is a major retrospective study published in June 2024 in ACR Open Rheumatology that analyzed data from more than 9,000 lupus patients taking metformin. The researchers found that these patients had a significantly lower risk of developing lupus nephritis, chronic kidney disease, and cardiovascular events compared to those not taking the drug.
While large-scale clinical trials are the gold standard, real-world patient experiences often pave the way for broader medical acceptance. Today, we’re sharing the compelling case study of a lupus patient (her name has been changed to protect her privacy) who successfully used metformin to help bring a dangerous disease under control.
The promise of metformin for treating lupus
To understand why metformin was associated with improved health in this individual, we must first consider its mechanism of action. Lupus is characterized by an overactive immune system that attacks healthy tissue. Current standard treatments for SLE include immunosuppressants to reduce immune overactivation, steroids to reduce pain and inflammation, and antimalarial drugs to reduce autoantibodies (proteins in the blood that attack healthy cells and tissues). These medications often come with severe toxicity and side effects.
Metformin may become a key medication for the treatment of SLE. Research indicates that metformin affects inflammation and the immune system by targeting the cellular metabolism of immune cells. Specifically, it inhibits the mTOR pathway, a critical regulator of cell growth and proliferation. In patients with lupus, T cells (immune cells) often exhibit hyperactive metabolism. Metformin essentially acts as a “metabolic brake,” reducing oxidative stress and inhibiting the production of inflammatory cytokines.
Metformin’s safety profile is also excellent. Gastrointestinal issues are the most common side effects and can be reduced by gradual dosing, time-release medication, and taking with food.
A lupus patient in crisis
“Julie’s” journey with lupus began long before her official diagnosis in 2017. Her history included immune-mediated thrombocytopenia, Hashimoto’s thyroiditis, and unexplained markers of inflammation. By 2022, her condition had escalated into a medical crisis involving her liver, kidneys, and vision. She was treated with high-dose immunosuppressants that caused severe side effects.
In April 2022, Julie suffered a near-fatal cardiac tamponade (fluid accumulation around the heart) requiring emergency open-heart surgery. Following the surgery, she was left with a persistent pericardial effusion (fluid in the sac surrounding the heart) and a diagnosis of borderline lupus nephritis (kidney involvement).
Her medication burden was immense. She was relying on high doses of methylprednisolone (40 mg/day) and immunosuppressants such as mycophenolate to survive. Her quality of life was deteriorating, and the side effects of the standard treatments were mounting.
The metformin intervention
Prompted by emerging literature and resources on the potential of metformin to treat autoimmune disorders, Julie approached her medical team. The response was mixed — a common hurdle for patients seeking off-label treatments. Her rheumatologist declined to prescribe it due to its non-standard status. However, her endocrinologist was familiar with the benefits of metformin and agreed to prescribe a low dose.
Through self-advocacy and careful monitoring, Julie titrated her dose up to 1,500 mg/day (extended-release), a dosage often cited in literature as effective for immunomodulation.
Clinical outcome: dramatic improvement
The results of adding metformin to Julie’s regimen were quantifiable and significant.
- Liver Function: For the first time since her 2017 diagnosis, her liver enzymes normalized.
- Kidney Function: While her creatinine remains borderline, the critical marker of kidney stress — the 24-hour urine protein-creatinine ratio — returned to normal levels.
- Inflammation: Key inflammatory markers (CRP and PCR) dropped to completely normal ranges.
- Physical Recovery: Julie reports that her energy levels have returned to 75% of her pre-diagnosis level, with minimal joint stiffness and no need for pain medication.
Perhaps most remarkably, the addition of metformin allowed for a drastic reduction in medications with toxic side effects. Julie successfully weaned off all steroids and the immunosuppressant drug mycophenolate. She now maintains her health on 1,500 mg of metformin and just 200 mg/day of hydroxychloroquine.
Navigating complexity: The importance of diagnosis
Julie’s journey was not without challenges. During treatment, she experienced episodes of severe reactive hypoglycemia (fainting). Initially, her rheumatologist blamed the metformin and forced a one-month break from the drug.
This break proved to be a critical “re-challenge.” Without metformin, her lupus symptoms immediately returned, confirming the drug’s protective benefit. Her endocrinologist eventually identified the hypoglycemia as a rare, self-limiting complication of the lupus itself (after ruling out insulinoma), rather than a side effect of the metformin. This highlights the importance of a diverse medical team that understands both the disease and the pharmacological profile of repurposed drugs.
Looking forward to reducing the burden of lupus
Julie’s story is a powerful anecdote supporting what researchers are seeing in the lab: metformin has the potential to treat, and perhaps even correct, the defective cellular metabolism that drives lupus.
It’s important to note that metformin is not currently approved for the treatment of SLE. However, the body of evidence supporting this use is growing. Beyond the 2024 retrospective analysis mentioned above, numerous academic research groups continue to investigate metformin’s capacity to reduce disease flares and facilitate steroid tapering. Because metformin is a generic drug with low profit margins, large commercial clinical trials are rare; much of this progress relies on academic and nonprofit research.
For physicians, Julie’s case illustrates that metformin can be a safe, adjunctive therapy that may reduce the reliance on corticosteroids and prevent organ damage. For patients, it offers hope that an accessible, affordable medication could change the course of a debilitating disease.
To review the scientific literature regarding metformin and autoimmunity, please visit our Metformin Project Page. Here you can also find a handout with information to review or share with your physician.
The Parsemus Foundation provides this information for educational purposes. Patients should always consult with their physicians before making changes to their medication regimens.
